Eli Lilly and Company Revenue and Competitors
Estimated Revenue & Valuation
- Eli Lilly and Company's estimated annual revenue is currently $27.8B per year.
- Eli Lilly and Company's estimated revenue per employee is $625,267
- Eli Lilly and Company's current valuation is $233.5B. (January 2022)
Employee Data
- Eli Lilly and Company has 44397 Employees.
- Eli Lilly and Company grew their employee count by 4% last year.
Eli Lilly and Company Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.6M | 23 | 0% | N/A | N/A |
#2 | $23.5M | 117 | -28% | N/A | N/A |
#3 | $575.7M | 2864 | 2% | N/A | N/A |
#4 | $1.8M | 18 | -10% | $1.5M | N/A |
#5 | $5.8M | 29 | -6% | N/A | N/A |
#6 | $10.7M | 53 | 15% | N/A | N/A |
#7 | $271.4M | 1350 | 4% | N/A | N/A |
#8 | $9.2M | 46 | 10% | N/A | N/A |
#9 | $27760M | 44397 | 4% | N/A | N/A |
#10 | $1.2M | 6 | -54% | N/A | N/A |
What Is Eli Lilly and Company?
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaboration with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world\'s most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
keywords:N/A
N/A
Total Funding
44397
Number of Employees
$27.8B
Revenue (est)
4%
Employee Growth %
$233.5B
Valuation
N/A
Accelerator
Eli Lilly and Company's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate VP, Alzheimer's Global Marketing | Reveal Email/Phone |
2 | Associate VP, Corporate Risk Management | Reveal Email/Phone |
3 | Associate VP-Global and US Medical Affairs, Pain/Migraine | Reveal Email/Phone |
4 | N/A | Reveal Email/Phone |
5 | IT Consultant | Reveal Email/Phone |
6 | Sr. Director Quality Assurance | Reveal Email/Phone |
7 | Principal Research Associate | Reveal Email/Phone |
8 | COO, Senior Director Strategy and Planning Advanced Analytics and Data Science | Reveal Email/Phone |
9 | Director - Clinical Research Scientist | Reveal Email/Phone |
10 | Quality Assurance | Reveal Email/Phone |
Eli Lilly and Company News
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors. Published: April 20, 2022 at 5:04 p.m. ET. By. MarketWatch Automation.
INDIANAPOLIS , April 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of...
... in the ADvocate program, Eli Lilly and Company (NYSE: LLY) announced today at the American Academy of Dermatology (AAD) Annual Meeting.
INDIANAPOLIS, Oct. 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of horm ...
INDIANAPOLIS, Oct. 7, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that preclinical characterization data for two new agents, LOXO-783 and LOXO-435, will be presented at the 2021 AACR-NCI-EORTC Virtual Interna ...